Unbound MEDLINE

Synthesis of Ranolazine Metabolites and Their Anti-myocardial Ischemia Activities. Chemical & pharmaceutical bulletin [Chem Pharm Bull (Tokyo)] Journal article

 
TitleSynthesis of Ranolazine Metabolites and Their Anti-myocardial Ischemia Activities.
Author(s)Yao Z, Gong S, Guan T, Li Y, Wu X, Sun H 
InstitutionCenter for Drug Discovery, College of Pharmacy, China Pharmaceutical University.
SourceChem Pharm Bull (Tokyo) 2009 Nov; 57(11):1218-22.
AbstractThe anti-anginal drug Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, is thought to modulate the metabolism during myocardial ischemia by activating pyruvate dehydrogenase activity to promote glucose oxidation. Ranolazine and its five principal metabolites: CVT-2512, CVT-2513, CVT-2514, CVT-2738 and CVT-4786, were synthesized. The effect of Ranolazine and its metabolites on the ECG (electrocardiogram) of mice with myocardial ischemia induced by isoprenaline and their effect on alleviating the symptom of myocardial ischemia were tested and compared. The results showed that CVT-2738 and CVT-2513 could be protective against mice myocardial ischemia induced by isoprenaline. Within all the metabolites tested in this study, CVT-2738 exhibited the best potency, however, it was still less potent than Ranolazine.
Languageeng
Pub Type(s)Journal Article
PubMed ID19881270
  
Advertise on this site.